

# Daisuke Tomizawa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7908968/publications.pdf>

Version: 2024-02-01

150  
papers

3,700  
citations

126907

33  
h-index

155660

55  
g-index

152  
all docs

152  
docs citations

152  
times ranked

4589  
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute lymphoblastic leukemia in infants: A quarter century of nationwide efforts in Japan. <i>Pediatrics International</i> , 2022, 64, .	0.5	5
2	Vedolizumab therapy for pediatric steroid-refractory gastrointestinal acute graft-versus-host disease. <i>International Journal of Hematology</i> , 2022, 115, 590-594.	1.6	5
3	Genome-wide DNA methylation analysis in pediatric acute myeloid leukemia. <i>Blood Advances</i> , 2022, 6, 3207-3219.	5.2	7
4	Childhood acute myeloid leukemia with 5q deletion and <i>HNRNP1-MLLT10</i> fusion: the first case report. <i>Blood Advances</i> , 2022, 6, 3162-3166.	5.2	1
5	Delay in diagnosis of blood disorders due to corticosteroid administration. <i>Pediatrics International</i> , 2022, 64, e14997.	0.5	0
6	Quantitative assessment of copy number alterations by liquid biopsy for neuroblastoma. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 662-669.	2.8	6
7	Postchemotherapy immune status in infants with acute lymphoblastic leukemia: A report from the JPLSG MLL-10 trial. <i>Pediatric Blood and Cancer</i> , 2022, 69, .	1.5	2
8	Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study. <i>British Journal of Haematology</i> , 2021, 193, 176-180.	2.5	3
9	The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28736.	1.5	11
10	Long-term outcome in patients with Fanconi anemia who received hematopoietic stem cell transplantation: a retrospective nationwide analysis. <i>International Journal of Hematology</i> , 2021, 113, 134-144.	1.6	14
11	Targeting critical kinases and anti-apoptotic molecules overcomes steroid resistance in MLL-rearranged leukaemia. <i>EBioMedicine</i> , 2021, 64, 103235.	6.1	2
12	Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases. <i>Journal of Clinical Immunology</i> , 2021, 41, 944-957.	3.8	9
13	Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome. <i>Leukemia</i> , 2021, 35, 2508-2516.	7.2	5
14	Effect of extramedullary disease on allogeneic hematopoietic cell transplantation for pediatric acute myeloid leukemia: a nationwide retrospective study. <i>Bone Marrow Transplantation</i> , 2021, 56, 1859-1865.	2.4	4
15	Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia. <i>Haematologica</i> , 2021, , .	3.5	10
16	Two-point blood sampling is sufficient and necessary to estimate the area under the concentration-time curve for intravenous busulfan in infants and young children. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29069.	1.5	4
17	Droplet digital polymerase chain reaction assay for the detection of the minor clone of <i>KIT</i> D816V in paediatric acute myeloid leukaemia especially showing <i>RUNX1-RUNX1T1</i> transcripts. <i>British Journal of Haematology</i> , 2021, 194, 414-422.	2.5	2
18	Sudden unexpected death caused by infantile acute lymphoblastic leukaemia. <i>Oxford Medical Case Reports</i> , 2021, 2021, omab073.	0.4	1

#	ARTICLE	IF	CITATIONS
19	Genetic features of precursor B-cell phenotype Burkitt leukemia with IGH-MYC rearrangement. Cancer Reports, 2021, , e1545.	1.4	1
20	Hematopoietic stem cell transplantation for infants with high-risk <i>KMT2A</i> gene rearranged acute lymphoblastic leukemia. Blood Advances, 2021, 5, 3891-3899.	5.2	12
21	A Prospective Viral Monitoring Study After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation for Malignant and Nonmalignant Diseases. Transplantation and Cellular Therapy, 2021, 27, 872.e1-872.e8.	1.2	8
22	Successful Umbilical Cord Blood Transplantation With Reduced-intensity Conditioning for Acute Myeloid Leukemia in a Child With Shwachman-Diamond Syndrome. Journal of Pediatric Hematology/Oncology, 2021, 43, e414-e418.	0.6	2
23	Nonconditioned ADA-SCID gene therapy reveals ADA requirement in the hematopoietic system and clonal dominance of vector-marked clones. Molecular Therapy - Methods and Clinical Development, 2021, 23, 424-433.	4.1	5
24	<i>NUDT15</i> variants confer high incidence of second malignancies in children with acute lymphoblastic leukemia. Blood Advances, 2021, 5, 5420-5428.	5.2	4
25	Highly sensitive detection of <i>GATA1</i> mutations in patients with myeloid leukemia associated with Down syndrome by combining Sanger and targeted next generation sequencing. Genes Chromosomes and Cancer, 2020, 59, 160-167.	2.8	8
26	Patients aged less than 3 years with acute myeloid leukaemia characterize a molecularly and clinically distinct subgroup. British Journal of Haematology, 2020, 188, 528-539.	2.5	20
27	Comparison of clonazepam and levetiracetam in children for prevention of busulfan-induced seizure in hematopoietic stem cell transplantation. International Journal of Hematology, 2020, 111, 463-466.	1.6	5
28	Tacrolimus blood concentration increase depends on administration route when combined with voriconazole in pediatric stem cell transplant recipients. Pediatric Transplantation, 2020, 24, e13619.	1.0	3
29	Fusion partner-specific mutation profiles and KRAS mutations as adverse prognostic factors in MLL-rearranged AML. Blood Advances, 2020, 4, 4623-4631.	5.2	7
30	Prospective Study of Allogeneic Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide and Antithymocyte Globulin from HLA-Mismatched Related Donors for Nonmalignant Diseases. Biology of Blood and Marrow Transplantation, 2020, 26, e286-e291.	2.0	14
31	Attempts to optimize postinduction treatment in childhood acute myeloid leukemia without core-binding factors: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG). Pediatric Blood and Cancer, 2020, 67, e28692.	1.5	8
32	A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial. Blood, 2020, 136, 1813-1823.	1.4	61
33	EV1 triggers metabolic reprogramming associated with leukemogenesis and increases sensitivity to L-asparaginase. Haematologica, 2020, 105, 2118-2129.	3.5	17
34	Hematopoietic stem cell transplantation for pediatric acute promyelocytic leukemia in Japan. Pediatric Blood and Cancer, 2020, 67, e28181.	1.5	3
35	Infant ALL. , 2020, , 81-91.		0
36	Impact of graft-versus-host disease on relapse and survival after allogeneic stem cell transplantation for pediatric leukemia. Bone Marrow Transplantation, 2019, 54, 68-75.	2.4	49

#	ARTICLE	IF	CITATIONS
37	Allogeneic hematopoietic stem cell transplantation for children and adolescents with high-risk cytogenetic AML: distinctly poor outcomes of FUS-ERG-positive cases. Bone Marrow Transplantation, 2019, 54, 393-401.	2.4	15
38	A prospective study of allogeneic transplantation from unrelated donors for chronic granulomatous disease with target busulfan-based reduced-intensity conditioning. Bone Marrow Transplantation, 2019, 54, 168-172.	2.4	10
39	Characteristics and outcomes of children with acute myeloid leukemia and Down syndrome who are ineligible for clinical trials due to severe comorbidities. Pediatric Blood and Cancer, 2019, 66, e27942.	1.5	2
40	Retrospective analysis of children with high-risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AML-05 clinical trial. Pediatric Blood and Cancer, 2019, 66, e27875.	1.5	12
41	Acute promyelocytic leukemia with a cryptic insertion of <i>RARA</i> into <i>TBL1XR1</i> . Genes Chromosomes and Cancer, 2019, 58, 820-823.	2.8	13
42	Negative CD19 expression is associated with inferior relapse-free survival in children with <i>RUNX1-RUNX1T1</i> -positive acute myeloid leukaemia: results from the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study. British Journal of Haematology, 2019, 187, 372-376.	2.5	12
43	Personalized pharmacokinetic targeting with busulfan in allogeneic hematopoietic stem cell transplantation in infants with acute lymphoblastic leukemia. International Journal of Hematology, 2019, 110, 355-363.	1.6	9
44	A novel <i>KMT2A-CTN2</i> fusion in infant B-cell acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2019, 66, e27821.	1.5	0
45	Whole transcriptome sequencing reveals a <i>KMT2A-USP2</i> fusion in infant acute myeloid leukemia. Genes Chromosomes and Cancer, 2019, 58, 669-672.	2.8	9
46	Genomic subtyping and therapeutic targeting of acute erythroleukemia. Nature Genetics, 2019, 51, 694-704.	21.4	97
47	Hematopoietic stem-cell transplantation in children with refractory acute myeloid leukemia. Bone Marrow Transplantation, 2019, 54, 1489-1498.	2.4	13
48	Clinical and biological features of paediatric acute myeloid leukaemia (AML) with primary induction failure in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study. British Journal of Haematology, 2019, 185, 284-288.	2.5	12
49	Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia. Blood Advances, 2019, 3, 3157-3169.	5.2	51
50	Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia patients with KMT2A rearrangement; A nationwide retrospective analysis in Japan. Leukemia Research, 2019, 87, 106263.	0.8	5
51	Total body irradiation for hematopoietic stem cell transplantation during early childhood is associated with the risk for diabetes mellitus. Endocrine, 2018, 61, 76-82.	2.3	4
52	Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study. International Journal of Hematology, 2018, 107, 586-595.	1.6	20
53	Somatic <i>MECOM</i> mosaicism in a patient with congenital bone marrow failure without a radial abnormality. Pediatric Blood and Cancer, 2018, 65, e26959.	1.5	12
54	Treatment outcome of children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group (TCCSG) Study L04-16. International Journal of Hematology, 2018, 108, 98-108.	1.6	43

#	ARTICLE	IF	CITATIONS
55	Monitoring of fusion gene transcripts to predict relapse in pediatric acute myeloid leukemia. <i>Pediatrics International</i> , 2018, 60, 41-46.	0.5	13
56	Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia. <i>International Journal of Hematology</i> , 2018, 107, 201-210.	1.6	15
57	Multiplex fusion gene testing in pediatric acute myeloid leukemia. <i>Pediatrics International</i> , 2018, 60, 47-51.	0.5	12
58	Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group. <i>Blood</i> , 2018, 132, 1584-1592.	1.4	45
59	Recurrent CCND3 mutations in MLL-rearranged acute myeloid leukemia. <i>Blood Advances</i> , 2018, 2, 2879-2889.	5.2	19
60	Diploidy analysis of NUDT15 variants and 6-mercaptopurine sensitivity in pediatric lymphoid neoplasms. <i>Leukemia</i> , 2018, 32, 2710-2714.	7.2	26
61	RUNX1 mutations in pediatric acute myeloid leukemia are associated with distinct genetic features and an inferior prognosis. <i>Blood</i> , 2018, 131, 2266-2270.	1.4	15
62	Evaluation of high-dose cytarabine in induction therapy for children with de novo acute myeloid leukemia: a study protocol of the Japan Children's Cancer Group Multi-Center Seamless Phase II/III Randomized Trial (JPLSG AML-12). <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 587-593.	1.3	18
63	Recurrent <i>RARB</i> Translocations in Acute Promyelocytic Leukemia Lacking <i>RARA</i> Translocation. <i>Cancer Research</i> , 2018, 78, 4452-4458.	0.9	37
64	<i>ASXL2</i> mutations are frequently found in pediatric AML patients with t(8;21)/ <i>RUNX1</i> and associated with a better prognosis. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 382-393.	2.8	18
65	Prognostic impact of specific molecular profiles in pediatric acute megakaryoblastic leukemia in non-Down syndrome. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 394-404.	2.8	51
66	HLA haploidentical hematopoietic cell transplantation using clofarabine and busulfan for refractory pediatric hematological malignancy. <i>International Journal of Hematology</i> , 2017, 105, 686-691.	1.6	7
67	Outcome of relapsed core binding factor acute myeloid leukemia in children: A result from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML05R study. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26491.	1.5	5
68	Plasma asparaginase activity, asparagine concentration, and toxicity after administration of <i>Erwinia</i> asparaginase in children and young adults with acute lymphoblastic leukemia: Phase I/II clinical trial in Japan. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26475.	1.5	3
69	Allogeneic Hematopoietic Stem Cell Transplantation for Adolescents and Young Adults with Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1515-1522.	2.0	24
70	Acute lymphoblastic leukemia in patients with Down syndrome with a previous history of acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26411.	1.5	4
71	Azacitidine successfully maintained the second remission in an infant with <i>KMT2A</i> -rearranged acute lymphoblastic leukemia who relapsed after unrelated cord blood transplantation. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26697.	1.5	7
72	Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia. <i>Pediatrics International</i> , 2017, 59, 1046-1052.	0.5	7

#	ARTICLE	IF	CITATIONS
73	Down syndrome and AML: where do we go from here?. Blood, 2017, 129, 3274-3275.	1.4	4
74	Acute Lymphoblastic Leukemia. , 2017, , 33-60.		3
75	Acute Myeloid Leukemia. , 2017, , 61-85.		0
76	<i>CXCR4</i> Overexpression is a Poor Prognostic Factor in Pediatric Acute Myeloid Leukemia With Low Risk: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group. Pediatric Blood and Cancer, 2016, 63, 1394-1399.	1.5	11
77	High <i>PRDM16</i> expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to <i>FLT3</i> and <i>ITD</i> , <i>KMT2A</i> and <i>PTD</i> , and <i>NUP98</i> and <i>NSD1</i> : the results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML05 trial. British Journal of Haematology, 2016, 172, 581-591.	2.5	41
78	Whole-exome sequencing reveals the spectrum of gene mutations and the clonal evolution patterns in paediatric acute myeloid leukaemia. British Journal of Haematology, 2016, 175, 476-489.	2.5	60
79	Acute myeloid leukemia in children: Current status and future directions. Pediatrics International, 2016, 58, 71-80.	0.5	71
80	EWSR1/ELF5 induces acute myeloid leukemia by inhibiting p53/p21 pathway. Cancer Science, 2016, 107, 1745-1754.	3.9	17
81	Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan. Pediatric Blood and Cancer, 2016, 63, 248-254.	1.5	33
82	Recent progress in the treatment of infant acute lymphoblastic leukemia. Pediatrics International, 2015, 57, 811-819.	0.5	29
83	Identification of CD34+ and CD34 <sup>low</sup> leukemia-initiating cells in MLL-rearranged human acute lymphoblastic leukemia. Blood, 2015, 125, 967-980.	1.4	47
84	Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study. Blood, 2015, 126, 1575-1584.	1.4	69
85	<i>CSF3R</i> and <i>CALR</i> mutations in paediatric myeloid disorders and the association of <i>CSF3R</i> mutations with translocations, including t(8; 21). British Journal of Haematology, 2015, 170, 391-397.	2.5	18
86	Outcome of adolescent patients with acute myeloid leukemia treated with pediatric protocols. International Journal of Hematology, 2015, 102, 318-326.	1.6	17
87	High expression of EVI1 and MEL1 is a compelling poor prognostic marker of pediatric AML. Leukemia, 2015, 29, 1076-1083.	7.2	42
88	Adverse prognostic impact of KIT mutations in childhood CBF-AML: the results of the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 trial. Leukemia, 2015, 29, 2438-2441.	7.2	28
89	Clinical features and hematopoietic stem cell transplantations for CD40 ligand deficiency in Japan. Journal of Allergy and Clinical Immunology, 2015, 136, 1018-1024.	2.9	48
90	Respiratory syncytial virus infection in infants with acute leukemia: a retrospective survey of the Japanese Pediatric Leukemia/Lymphoma Study Group. International Journal of Hematology, 2015, 102, 697-701.	1.6	5

#	ARTICLE	IF	CITATIONS
91	Favorable outcome in non-infant children with MLL-AF4-positive acute lymphoblastic leukemia: a report from the Tokyo Children's Cancer Study Group. <i>International Journal of Hematology</i> , 2015, 102, 602-610.	1.6	7
92	Transient abnormal myelopoiesis in non-twin syndrome neonate. <i>Pediatrics International</i> , 2015, 57, e14-7.	0.5	3
93	Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A Report From the Japanese Society for Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2141-2147.	2.0	17
94	Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2015, 33, 2949-2962.	1.6	277
95	Early use of allogeneic hematopoietic stem cell transplantation for infants with MLL gene-rearrangement-positive acute lymphoblastic leukemia. <i>Leukemia</i> , 2015, 29, 290-296.	7.2	51
96	Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group. <i>Blood Cancer Journal</i> , 2014, 4, e226-e226.	6.2	26
97	t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients. <i>Haematologica</i> , 2014, 99, 865-872.	3.5	77
98	Cord blood transplantation is associated with rapid B-cell neogenesis compared with BM transplantation. <i>Bone Marrow Transplantation</i> , 2014, 49, 1155-1161.	2.4	24
99	Acute myeloid leukaemia with myelodysplastic features in children: a report of Japanese Paediatric Leukaemia/Lymphoma Study Group. <i>British Journal of Haematology</i> , 2014, 167, 80-86.	2.5	19
100	Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocol. <i>International Journal of Hematology</i> , 2014, 100, 171-179.	1.6	31
101	EVII overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia. <i>Haematologica</i> , 2014, 99, e225-e227.	3.5	35
102	Phase I/II Clinical Trial of Erwinia Asparaginase (ErwinaseR) in Combination with Prednisolone, Vincristine and Pirarubicin in Children and Young Adults with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL). <i>Blood</i> , 2014, 124, 3657-3657.	1.4	1
103	Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group. <i>International Journal of Hematology</i> , 2013, 98, 578-588.	1.6	47
104	Early coagulation disorder after allogeneic stem cell transplantation is a strong prognostic factor for transplantation-related mortality, and intervention with recombinant human thrombomodulin improves the outcome: a single-center experience. <i>International Journal of Hematology</i> , 2013, 98, 533-542.	1.6	12
105	Comparison of Intravenous with Oral Busulfan in Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Regimens for Pediatric Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1690-1694.	2.0	20
106	Successful Treatment of Diffuse Large B-Cell Lymphoma in a Patient With Ataxia Telangiectasia Using Rituximab. <i>Journal of Pediatric Hematology/Oncology</i> , 2013, 35, 482-485.	0.6	12
107	Kasabach-Merritt Phenomenon. <i>Journal of Pediatric Hematology/Oncology</i> , 2013, 35, 554-558.	0.6	28
108	Excess treatment reduction including anthracyclines results in higher incidence of relapse in core binding factor acute myeloid leukemia in children. <i>Leukemia</i> , 2013, 27, 2413-2416.	7.2	52

#	ARTICLE	IF	CITATIONS
109	Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Münster AML-study group. Blood, 2013, 122, 2704-2713.	1.4	86
110	Irreversible Leukoencephalopathy After Reduced-intensity Stem Cell Transplantation in a Dyskeratosis Congenita Patient With TINF2 Mutation. Journal of Pediatric Hematology/Oncology, 2013, 35, e178-e182.	0.6	4
111	CSF3R Gene Mutations In Myeloid Malignancy Of Childhood. Blood, 2013, 122, 1352-1352.	1.4	2
112	Low Frequency and Poor Prognosis Of MLL-Partial Tandem Duplications In Pediatric Acute Myeloid Leukemia Using MLPA Method: The Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05 Trial. Blood, 2013, 122, 1374-1374.	1.4	0
113	Whole-Exome Resequencing Identifies Somatic Mutations Of BCOR and BCORL1 Transcriptional Corepressor Genes and Major Cohesin Complex Component Genes In Pediatric Acute Myeloid Leukemia. Blood, 2013, 122, 834-834.	1.4	0
114	Double CEBPA Mutations Are Not Associated With Favorable Clinical Outcome In Pediatric AML: A Report From The Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG). Blood, 2013, 122, 4942-4942.	1.4	0
115	Comparison Of Intravenous With Oral Busulfan In Allogeneic Hematopoietic Stem Cell Transplantation With Myeloablative Conditioning Regimens For Pediatric Acute Leukemia. Blood, 2013, 122, 3397-3397.	1.4	1
116	Comprehensive Fusion Gene Analysis Of Pediatric Non-Down Syndrome Acute Megakaryoblastic Leukemia. Blood, 2013, 122, 2646-2646.	1.4	0
117	Poor Prognosis With Different Induction Rate Was Observed In Children With Acute Myeloid Leukemia and FLT3-ITD According To The ITD/WT Allelic Ratio: A Result From The Japanese Pediatric Leukemia/Lymphoma Study Group. Blood, 2013, 122, 3891-3891.	1.4	0
118	Significance Of Minimal Residual Disease Detected By Multi-Color Flow Cytometry In Childhood Acute Myeloid Leukemia With The Intermediate-Risk Cytogenetics and Negative FMS-Like Tyrosine Kinase 3 Internal Tandem Duplication: A Report Of The Tokyo Children's Cancer Study Group. Blood, 2013, 122, 1416-1416.	1.4	0
119	Clinical characteristics and outcome of refractory/relapsed myeloid leukemia in children with Down syndrome. Blood, 2012, 120, 1810-1815.	1.4	46
120	An Inv(16)(p13.3q24.3)-Encoded CBFA2T3-GLIS2 Fusion Protein Defines an Aggressive Subtype of Pediatric Acute Megakaryoblastic Leukemia. Cancer Cell, 2012, 22, 683-697.	16.8	213
121	Excess Reduction of Anthracyclines Results in Inferior Event-Free Survival in Core Binding Factor Acute Myeloid Leukemia in Children; A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG). Blood, 2012, 120, 409-409.	1.4	1
122	Effect of KIR Ligand Mismatched SCT for Infantile ALL with MLL gene Rearrangement: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG). Blood, 2012, 120, 4543-4543.	1.4	0
123	Appropriate Dose Modification in Induction Therapy Is Essential for the Treatment of Infants with Acute Myeloid Leukemia; A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG).. Blood, 2012, 120, 2615-2615.	1.4	0
124	Myelodysplasia-Related Changes Have Adverse Prognostic Significance in Children with Acute Myeloid Leukemia; A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG).. Blood, 2012, 120, 2583-2583.	1.4	0
125	Attempts to Optimize Post-Induction Treatment in Childhood Acute Myeloid Leukemia without Core Binding Factors: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG). Blood, 2012, 120, 3545-3545.	1.4	1
126	Translocation t(6;9)(p22;q34)/DEK-NUP214 rearranged Pediatric AML: A Retrospective International Study. Blood, 2012, 120, 538-538.	1.4	6

#	ARTICLE	IF	CITATIONS
127	Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. <i>Blood</i> , 2011, 117, 7102-7111.	1.4	58
128	Outcome of unrelated umbilical cord blood transplantation in 88 patients with primary immunodeficiency in Japan. <i>British Journal of Haematology</i> , 2011, 154, 363-372.	2.5	56
129	Heterogeneity in Infants with Acute Myeloid Leukemia: Retrospective Analysis of a Japanese Nationwide Survey. <i>Blood</i> , 2011, 118, 1477-1477.	1.4	0
130	Refractory / Relapsed Myeloid Leukemia of Down Syndrome Is Resistant to Second-Line Chemotherapy and Hardly Salvaged by Hematopoietic Stem Cell Transplantation: A Retrospective Study by the Japanese Pediatric Leukemia / Lymphoma Study Group (JPLSG). <i>Blood</i> , 2011, 118, 4276-4276.	1.4	0
131	Long-term results of Tokyo Children's Cancer Study Group trials for childhood acute lymphoblastic leukemia, 1984-1999. <i>Leukemia</i> , 2010, 24, 383-396.	7.2	60
132	Unrelated Umbilical Cord Blood Transplantation for Patients with Primary Immunodeficiency: A Report From the Registry of the Japan Cord Blood Bank Network. <i>Blood</i> , 2010, 116, 3524-3524.	1.4	0
133	Immunologically silent cancer clone transmission from mother to offspring. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 17882-17885.	7.1	65
134	Outcome of recurrent or refractory acute lymphoblastic leukemia in infants with <i>MLL</i> gene rearrangements: A report from the Japan infant leukemia study group. <i>Pediatric Blood and Cancer</i> , 2009, 52, 808-813.	1.5	38
135	Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. <i>Blood</i> , 2009, 114, 2489-2496.	1.4	383
136	Suppression of Let-7b MicroRNA and Enhanced Its Target genes in Infant Acute Lymphoblastic Leukemia with MLL Gene Rearrangements.. <i>Blood</i> , 2009, 114, 986-986.	1.4	2
137	Loss of Non-Inherited Maternal MHC and Materno-Fetal Transmission of p190 Type BCR-ABL Leukemia.. <i>Blood</i> , 2009, 114, 980-980.	1.4	0
138	Clinical features and outcome of MLL gene rearranged acute lymphoblastic leukemia in infants with additional chromosomal abnormalities other than 11q23 translocation. <i>Leukemia Research</i> , 2008, 32, 1523-1529.	0.8	16
139	Nation-Wide Survey of Infant Leukemia in Japan: A Report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG).. <i>Blood</i> , 2008, 112, 896-896.	1.4	0
140	Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: Long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group. <i>Pediatric Blood and Cancer</i> , 2007, 49, 127-132.	1.5	48
141	Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group. <i>Leukemia</i> , 2007, 21, 2258-2263.	7.2	123
142	Hematopoietic stem cell transplantation for 30 patients with primary immunodeficiency diseases: 20 years experience of a single team. <i>Bone Marrow Transplantation</i> , 2006, 37, 469-477.	2.4	53
143	Infants with acute lymphoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone: results from the Japan Infant Leukemia Study Group. <i>Blood</i> , 2006, 107, 4663-4665.	1.4	48
144	Risk Stratification by MLL Gene Status and Outcome of Acute Lymphoblastic Leukemia in Infants: A Report from the Japan Infant Leukemia Study Group.. <i>Blood</i> , 2006, 108, 148-148.	1.4	0

#	ARTICLE	IF	CITATIONS
145	Analysis of serum soluble CD40 ligand (sCD40L) in the patients undergoing allogeneic stem cell transplantation: platelet is a major source of serum sCD40L. <i>European Journal of Haematology</i> , 2005, 74, 54-60.	2.2	26
146	Novel adopted immunotherapy for mixed chimerism after unrelated cord blood transplantation in Omenn syndrome. <i>European Journal of Haematology</i> , 2005, 75, 441-444.	2.2	32
147	Pancytopenia presenting with monosomy 7 which disappeared after immunosuppressive therapy. <i>Leukemia Research</i> , 2004, 28, 315-319.	0.8	9
148	Allogeneic hematopoietic stem cell transplantation for seven children with X-linked hyper-IgM syndrome: A single center experience. <i>American Journal of Hematology</i> , 2004, 76, 33-39.	4.1	41
149	Invasive Subglottal Aspergillosis in a Patient with Severe Aplastic Anemia: A Case Report. <i>Journal of Infection</i> , 2002, 44, 198-201.	3.3	14
150	A phase III clinical trial evaluating efficacy and safety of minimal residual disease-based risk stratification for children with acute myeloid leukemia, incorporating a randomized study of gemtuzumab ozogamicin in combination with post-induction chemotherapy for non-low-risk patients (JPLSG-AML-20). <i>Japanese Journal of Clinical Oncology</i> , 0, , .	1.3	2